insights_auto
Outlook: 64.7% bullish·11.8% bearish
Go to analysischevron_right
ARGX:NASDAQ
argenx SE - ADR
928,44 $
0,00%
(0,00) 1D
825,00 $
arrow_downward
-11,14% (-103,44)todayPre-market
Closed: 7 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARGX...
Mkt. cap
58,78 млрд
Avg. vol.
263,56 м.
Volume
100,31 м.
P/E ratio
35,27
52-wk high
1 072,75 $
52-wk low
661,85 $
EPS
26,32 $
Beta
0,45
Shares outstanding
62,89 млн
No. of employees
2 мың
Mkt. cap
58,78 млрд
Avg. vol.
263,56 м.
Volume
100,31 м.
P/E ratio
35,27
52-wk high
1 072,75 $
52-wk low
661,85 $
EPS
26,32 $
Beta
0,45
Shares outstanding
62,89 млн
No. of employees
2 мың
News stories
From web sources and news partners
GuruFocus
·
50 минут бұрын
argenx (ARGX) Shares Drop 14.2% Pre-Market Amid Market Uncertain
Yahoo Finance
·
58 минут бұрын
Why Is ARGX Stock Plunging Today?
Benzinga
·
1 сағат бұрын
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About argenx SE - ADR